JP2024522817A - フェニルピロールアミノグアニジン塩及び製剤 - Google Patents

フェニルピロールアミノグアニジン塩及び製剤 Download PDF

Info

Publication number
JP2024522817A
JP2024522817A JP2023578136A JP2023578136A JP2024522817A JP 2024522817 A JP2024522817 A JP 2024522817A JP 2023578136 A JP2023578136 A JP 2023578136A JP 2023578136 A JP2023578136 A JP 2023578136A JP 2024522817 A JP2024522817 A JP 2024522817A
Authority
JP
Japan
Prior art keywords
oral formulation
pharma
ceutically acceptable
acceptable salt
pyrrol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023578136A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522817A5 (cg-RX-API-DMAC7.html
Inventor
ボーセン,トーマス
ジョナッセン,トーマス,エンゲルブレット,ノードキルド
ホイガード,ベント
Original Assignee
シナクト ファーマ エーピーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シナクト ファーマ エーピーエス filed Critical シナクト ファーマ エーピーエス
Publication of JP2024522817A publication Critical patent/JP2024522817A/ja
Publication of JP2024522817A5 publication Critical patent/JP2024522817A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/83—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/02—Formic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/02—Formic acid
    • C07C53/06—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/14—Adipic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/347—Saturated compounds containing more than one carboxyl group containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C07C59/50—Mandelic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
JP2023578136A 2021-06-21 2022-06-21 フェニルピロールアミノグアニジン塩及び製剤 Pending JP2024522817A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP21180708 2021-06-21
EP21180708.6 2021-06-21
EP21180702.9 2021-06-21
EP21180702 2021-06-21
EP21209855 2021-11-23
EP21209855.2 2021-11-23
PCT/EP2022/066906 WO2022268825A1 (en) 2021-06-21 2022-06-21 Phenyl pyrrole aminoguanidine salts and formulations

Publications (2)

Publication Number Publication Date
JP2024522817A true JP2024522817A (ja) 2024-06-21
JP2024522817A5 JP2024522817A5 (cg-RX-API-DMAC7.html) 2025-06-30

Family

ID=84544160

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023578136A Pending JP2024522817A (ja) 2021-06-21 2022-06-21 フェニルピロールアミノグアニジン塩及び製剤
JP2023578832A Pending JP2024523459A (ja) 2021-06-21 2022-06-21 フェニルピロールアミノグアニジンの塩及びフェニルピロールアミノグアニジウム塩の多形体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023578832A Pending JP2024523459A (ja) 2021-06-21 2022-06-21 フェニルピロールアミノグアニジンの塩及びフェニルピロールアミノグアニジウム塩の多形体

Country Status (11)

Country Link
US (3) US12661336B2 (cg-RX-API-DMAC7.html)
EP (3) EP4359383A1 (cg-RX-API-DMAC7.html)
JP (2) JP2024522817A (cg-RX-API-DMAC7.html)
KR (2) KR20240024818A (cg-RX-API-DMAC7.html)
AU (2) AU2022296767A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023026909A2 (cg-RX-API-DMAC7.html)
CA (2) CA3220756A1 (cg-RX-API-DMAC7.html)
ES (1) ES3045575T3 (cg-RX-API-DMAC7.html)
IL (2) IL309102A (cg-RX-API-DMAC7.html)
MX (2) MX2023014174A (cg-RX-API-DMAC7.html)
WO (2) WO2022268825A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024523459A (ja) * 2021-06-21 2024-06-28 シナクト ファーマ エーピーエス フェニルピロールアミノグアニジンの塩及びフェニルピロールアミノグアニジウム塩の多形体

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3175172A1 (en) * 2020-03-31 2021-10-07 Synact Pharma Aps Treatment of symptomatic viral diseases
EP4522160A1 (en) * 2022-05-12 2025-03-19 SynAct Pharma ApS Resomelagon and its derivatives for the treatment of cardiovascular disease, hypertension and atherosclerosis
EP4637921A1 (en) * 2022-12-21 2025-10-29 SynAct Pharma ApS Polymorph of phenyl pyrrole hydrazine carboximidamide compound
AU2024398488A1 (en) 2023-12-11 2026-06-04 Synact Pharma Aps Treatment of subpopulation of patients with rheumatoid arthritis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020229297A1 (en) * 2019-05-10 2020-11-19 Synact Pharma Aps Combination treatment of arthritic disease

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604348D0 (sv) 1996-11-26 1996-11-26 Wapharm Ab Användning av hydroxyguanidiner
AU7464998A (en) 1997-10-27 1999-05-17 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
US6127381A (en) 1998-04-28 2000-10-03 Basu; Amaresh Isoquinoline compound melanocortin receptor ligands and methods of using same
AU742425B2 (en) 1998-06-11 2002-01-03 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
HK1044954B (en) 1999-03-29 2008-11-21 The Procter & Gamble Company Melanocortin receptor ligands
WO2000074679A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
AU6605800A (en) 1999-07-16 2001-02-05 Trega Biosciences, Inc. Melanocortin receptor-3 ligands to treat sexual dysfunction
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
AU781880B2 (en) 1999-09-17 2005-06-16 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US6720317B1 (en) 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
CZ2002961A3 (cs) 1999-09-17 2002-08-14 Millennium Pharmaceuticals, Inc. Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa
AU2001228681A1 (en) 2000-01-28 2001-08-07 Melacure Therapeutics Ab Novel aromatic amines and amides acting on the melanocortin receptors
WO2001055106A2 (en) 2000-01-28 2001-08-02 Melacure Therapeutics Ab Novel melanocortin receptor agonists and antagonists
GB0002059D0 (en) 2000-01-28 2000-03-22 Melacure Therapeutics Ab Novel aromatic amines
KR100440370B1 (ko) 2000-04-01 2004-07-19 (주)명문엘씨 2중 사출에 의한 밀폐용기 뚜껑
GB0019357D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
DZ3415A1 (fr) 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
US20030069169A1 (en) 2001-03-02 2003-04-10 Macor John E. Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders
GB0119172D0 (en) 2001-08-06 2001-09-26 Melacure Therapeutics Ab Phenyl pyrrole derivatives
CA2363528A1 (en) 2001-11-19 2003-05-19 Merck Patent Gesellschaft Mit Beschraenkter Haftung Immediate release tablet containing naproxen sodium
GB2398299A (en) 2003-02-13 2004-08-18 Melacure Therapeutics Ab Pharmaceutically active phenyl-pyrrole derivatives
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
SI2348016T1 (sl) 2006-06-09 2016-10-28 Synact Pharma Aps Derivati fenil pirol aminogvanidina
GB0624987D0 (en) 2006-12-14 2007-01-24 Acure Pharma Ab Novel aminoguanidines as melanocortin receptor ligands
EP2045250A1 (en) 2007-09-26 2009-04-08 Action Pharma A/S Ring-substituted phenyl pyrrole aminoguanidine derivatives
WO2009071101A1 (en) 2007-12-07 2009-06-11 Action Pharma A/S N-modified aminoguanidine derivatives
WO2009074157A1 (en) 2007-12-13 2009-06-18 Action Pharma A/S Fully-modified phenyl pyrrole aminoguanidines
US10387927B2 (en) 2010-01-15 2019-08-20 Dell Products L.P. System and method for entitling digital assets
EA201290860A1 (ru) 2010-03-03 2013-04-30 Тева Фармасьютикал Индастриз Лтд. Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата
JP2011190199A (ja) 2010-03-12 2011-09-29 Hideto Nakamura 関節リウマチ薬
US9662807B2 (en) 2011-12-21 2017-05-30 GKN Aerospace Services Structures, Corp. Method for forming a fabric preform for a composite material by separately tensioning tows
WO2014060606A1 (en) 2012-10-19 2014-04-24 Txp Pharma Gmbh Alpha- and gamma-msh analogues
US9917808B2 (en) 2013-03-14 2018-03-13 International Business Machines Corporation Grouping electronic messages
WO2015162483A1 (en) 2014-04-22 2015-10-29 Txp Pharma Gmbh Alpha- and gamma-msh analogues
WO2015162486A1 (en) 2014-04-22 2015-10-29 Txp Pharma Gmbh Linear gamma msh with c- and / or n-terminal extensions of lysine and / or glutamic acid residues
WO2017141343A1 (ja) 2016-02-16 2017-08-24 三菱電機株式会社 圧縮機
ES2899200T3 (es) 2018-06-22 2022-03-10 Synact Pharma Aps Tratamiento de proteinuria
WO2020107221A1 (en) 2018-11-27 2020-06-04 Tsinghua University Chemical activators of nicotinamide mononucleotide adenlyly transferase 2 (nmnat2) and uses thereof
CA3175172A1 (en) * 2020-03-31 2021-10-07 Synact Pharma Aps Treatment of symptomatic viral diseases
CN113730797B (zh) 2020-05-29 2023-05-16 创领心律管理医疗器械(上海)有限公司 电极板及可穿戴式除颤设备
IL309102A (en) * 2021-06-21 2024-02-01 Synact Pharma Aps Salts and formulations of phenyl pyrrole aminoguanidine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020229297A1 (en) * 2019-05-10 2020-11-19 Synact Pharma Aps Combination treatment of arthritic disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J PHARMACEUTICAL SCIENCES, vol. 107:419-425, JPN6026021522, 2018, ISSN: 0005875217 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024523459A (ja) * 2021-06-21 2024-06-28 シナクト ファーマ エーピーエス フェニルピロールアミノグアニジンの塩及びフェニルピロールアミノグアニジウム塩の多形体

Also Published As

Publication number Publication date
EP4359076A1 (en) 2024-05-01
JP2024523459A (ja) 2024-06-28
AU2022296767A1 (en) 2024-02-01
AU2022300305A1 (en) 2024-01-25
EP4359076C0 (en) 2025-08-06
US20230114865A1 (en) 2023-04-13
KR20240024818A (ko) 2024-02-26
EP4359076B1 (en) 2025-08-06
IL309104A (en) 2024-02-01
US12239631B2 (en) 2025-03-04
EP4684835A2 (en) 2026-01-28
US20230271922A9 (en) 2023-08-31
WO2022268825A1 (en) 2022-12-29
ES3045575T3 (en) 2025-11-28
CA3220753A1 (en) 2022-12-29
MX2023014174A (es) 2024-03-01
US20230002319A1 (en) 2023-01-05
IL309102A (en) 2024-02-01
WO2022268814A1 (en) 2022-12-29
BR112023026909A2 (pt) 2024-03-05
MX2023014177A (es) 2024-03-26
KR20240024177A (ko) 2024-02-23
US12661336B2 (en) 2026-06-23
US20240335423A1 (en) 2024-10-10
EP4684835A3 (en) 2026-04-08
CA3220756A1 (en) 2022-12-29
EP4359383A1 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
ES3045575T3 (en) Phenyl pyrrole aminoguanidine salts and formulations
JP6612200B2 (ja) 抗炎症性の置換シクロブテンジオン化合物のコリン塩
US12102637B2 (en) Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
US20100209495A1 (en) Granulates, process for preparing them and pharmaceutical products containing them
JP2010511663A5 (cg-RX-API-DMAC7.html)
US20190054088A1 (en) Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis
JP2009534462A (ja) ニメスリドを含有する新規な低用量医薬組成物、その調製および使用
CN107205969B (zh) 糖尿病治疗用药物组合物
CN101237858A (zh) 胃滞留制剂及其制备方法
US20250170065A1 (en) Therapeutic compounds, formulations, and use thereof
CA3245018A1 (en) THERAPEUTIC COMPOUNDS, FORMULATIONS AND THEIR USE
JP2814513B2 (ja) 溶出性の改良された製剤組成物
JPH0140009B2 (cg-RX-API-DMAC7.html)
BR122025026872A2 (pt) Forma de dosagem sólida oral de liberação imediata e seu uso
JP3122730B2 (ja) ロキソプロフェン・ナトリウム含有錠剤製剤
JP7355846B2 (ja) 固形製剤
HK40110368A (en) Phenyl pyrrole aminoguanidine salts and formulations
HK40110368B (en) Phenyl pyrrole aminoguanidine salts and formulations
JP2000264839A (ja) 結腸領域で高まった疼痛感応性と関連する機能障害及び/又は下行腸管の疾患の治療及び/又は予防のための医薬調剤並びにその製造法
CN117642382A (zh) 苯基吡咯氨基胍盐和制剂
RU2584653C2 (ru) Фармацевтическая композиция с пролонгированным высвобождением с антипсихотической активностью и способы её получения
WO2025162195A1 (zh) 包衣复方片剂
TR2023018923A2 (tr) Li̇nagli̇pti̇n ve metformi̇n i̇çeren farmasöti̇k tablet formülasyonlari
EA052180B1 (ru) Терапевтические соединения, составы и их применение
JPWO2020246526A1 (ja) キサンチンオキシダーゼ阻害剤含有腸溶性製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250620

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260602